LONDON and GAITHERSBURG, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the second quarter ended June 30, 2026.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.